The Psoriasis Ladder From Cream to Biologic

What is the psoriasis treatment ladder?

The ladder is a sequence of tiers ordered by how much of the body each one acts on: topical therapy first, then phototherapy, then drugs taken by mouth, then injected biologics. Each tier carries its own evidence base — the American Academy of Dermatology and the National Psoriasis Foundation publish a separate guideline for each, starting with topicals 1Ref 1American Academy of Dermatology; National Psoriasis Foundation (2021).Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures.That topical corticosteroids are recommended for non-intertriginous psoriasis plaques and that steroid-sparing agents — vitamin D analogues, tazarotene, and topical calcineurin inhibitors — carry the maintenance role and the intertriginous and facial sites; the first-line topical tier of the psoriasis ladder.. That structure is the point: these are distinct decisions, not one long protocol you serve time in.

What moves someone up. Three things, in practice. How much skin is involved. Which skin is involved. And whether the current step has done anything after a fair trial. A person with a few plaques on one shin and a person with plaques across both palms can have the same percentage of body surface affected and belong on completely different rungs, because hands do work that shins do not.

What does not move someone up. Time by itself. Waiting out a treatment that has plainly stopped helping is the most common way people lose years to this disease.

The ladder describes where treatments sit relative to one another. It does not require failing every lower rung before a higher one becomes appropriate.

If you have arrived here for a different condition, the adult eczema ladder and the acne treatment ladder are built on the same logic and top out in different places.

Rung one: what topical treatment is supposed to do

Topical therapy is the first rung and the only one most people with limited disease will ever need. The AAD-NPF topical guideline recommends topical corticosteroids for plaques outside the skin folds, alongside steroid-sparing agents — vitamin D analogues such as calcipotriene, the retinoid tazarotene, and topical calcineurin inhibitors — for maintenance and for sites where a potent steroid is a poor long-term choice 1Ref 1American Academy of Dermatology; National Psoriasis Foundation (2021).Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures.That topical corticosteroids are recommended for non-intertriginous psoriasis plaques and that steroid-sparing agents — vitamin D analogues, tazarotene, and topical calcineurin inhibitors — carry the maintenance role and the intertriginous and facial sites; the first-line topical tier of the psoriasis ladder..

The steroid-sparing half of that sentence is the part most often lost. Potent steroids work, and they are not meant to be applied to the same patch of skin indefinitely; the second agent exists to hold the ground the steroid took. A prescription that pairs them, or alternates them, is the guideline working as designed rather than a clinician hedging.

Why topicals appear to fail when they have not. Three ordinary reasons account for most of it. The amount applied is far smaller than the amount intended. The treatment stops the week a plaque flattens rather than continuing as directed. And thick scale sits between the medicine and the skin it is meant to reach — softening scale before application is not a folk remedy, it is how the drug gets in.

Topical-resistant psoriasis is a real and common category. But it is diagnosed after a fair trial applied properly, not after a tube that ran out in ten days.

Special sites change the cream, not the rung

Some skin cannot tolerate what other skin can, and the guideline handles those areas separately. Topical corticosteroids are recommended for non-intertriginous plaques — meaning plaques outside the folds — while steroid-sparing options including topical calcineurin inhibitors carry the load in the armpits, under the breasts, in the groin, and on the face, where potent steroids thin skin quickly 1Ref 1American Academy of Dermatology; National Psoriasis Foundation (2021).Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures.That topical corticosteroids are recommended for non-intertriginous psoriasis plaques and that steroid-sparing agents — vitamin D analogues, tazarotene, and topical calcineurin inhibitors — carry the maintenance role and the intertriginous and facial sites; the first-line topical tier of the psoriasis ladder..

Inverse psoriasis lives in exactly those folds and looks nothing like the silvery plaque most people picture. It is smooth, shiny, sharply bordered, and routinely mistaken for a yeast infection or simple chafing. It is among the most frequently mistreated presentations of this disease, and inverse psoriasis is the reason a dermatologist asks to look at areas the patient did not come in about.

The scalp takes solutions, foams, and shampoos rather than thick ointments, for the plain reason that people will not put grease in their hair twice a day. Nails are slow: the plate has to grow out before any improvement is visible, so the honest timescale is months, and nail involvement is one of the findings that raises the question of joints.

None of this moves anyone up or down the ladder. It changes the vehicle, the agent, and the expectation of how long the answer takes to arrive.

When creams stop working, what is the actual signal?

The signal is a fair trial, correctly applied, that produced no meaningful change — or disease so extensive that topical therapy is not a reasonable way to live. Applying cream twice a day to a third of your body is not a treatment plan; it is a second job. That practical ceiling is why the higher tiers exist: phototherapy, which the AAD-NPF treats as its own tier with its own indications and adverse effects 2Ref 2American Academy of Dermatology; National Psoriasis Foundation (2019).Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with phototherapy.That phototherapy for psoriasis — narrowband UVB, broadband UVB, PUVA, and excimer laser — is a distinct treatment tier with its own indications, contraindications, and adverse effects, delivered in measured, supervised amounts., and biologic therapy for moderate-to-severe disease 3Ref 3American Academy of Dermatology; National Psoriasis Foundation (2019).Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.That biologic therapy is recommended for moderate-to-severe psoriasis and is grouped by target class (TNF, IL-17, IL-23, IL-12/23), each with its own pre-treatment screening and ongoing safety monitoring..

What counts as a fair trial. Enough medicine, on de-scaled skin, for the period the prescription specified, with the steroid-sparing agent used as instructed rather than saved for a rainy day.

What escalates the conversation faster. Involvement of the genitals, palms, soles, scalp, or face, because those sites carry disability far out of proportion to their surface area. Any new joint symptom. And the plain fact of the disease running your calendar: clothing chosen for coverage, swimming abandoned, sleep broken by itch.

Psoriasis not responding to topical treatment is not a verdict on the patient, and it is not an argument for climbing the potency of the cream forever. It is the point where the question changes from what to put on the skin to what to say to the immune system.

Rung two: phototherapy

Phototherapy is ultraviolet light delivered on purpose, in measured amounts, under supervision. The AAD-NPF devotes a full guideline to it, covering narrowband UVB, broadband UVB, PUVA, and the excimer laser, together with the indications, contraindications, and adverse effects that separate them 2Ref 2American Academy of Dermatology; National Psoriasis Foundation (2019).Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with phototherapy.That phototherapy for psoriasis — narrowband UVB, broadband UVB, PUVA, and excimer laser — is a distinct treatment tier with its own indications, contraindications, and adverse effects, delivered in measured, supervised amounts.. Narrowband UVB is the workhorse for widespread plaque disease, and it remains one of the most underused effective treatments in dermatology.

What it asks of you. Repeat visits to a light booth, several times a week at the start. This rung succeeds or fails on logistics rather than biology: a unit fifteen minutes away is a different proposition from one an hour each way, and that geography is a legitimate reason a dermatologist skips this tier. Home units exist and are prescribed in some circumstances.

What it offers in return. No systemic drug, no ongoing blood monitoring, and a treatment that stays available in situations where suppressing the immune system broadly is unattractive. The excimer laser aims at a small number of stubborn plaques instead of the whole body.

What it is not. A tanning bed. A salon delivers an uncontrolled spectrum for an uncontrolled length of time, which is a different intervention entirely. The comparison matters precisely because ultraviolet light both helps psoriasis and damages skin — measured, supervised delivery is the whole point of the tier 2Ref 2American Academy of Dermatology; National Psoriasis Foundation (2019).Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with phototherapy.That phototherapy for psoriasis — narrowband UVB, broadband UVB, PUVA, and excimer laser — is a distinct treatment tier with its own indications, contraindications, and adverse effects, delivered in measured, supervised amounts..

Rung three: the drugs taken by mouth

Between phototherapy and biologics sit the systemic drugs given as pills — the older immune-modulating agents and the newer oral small molecules. They deliver systemic treatment without an injection, and for many people they are the practical middle of the ladder: familiar to prescribers, generally cheaper, and monitored with blood work rather than routed through a specialty pharmacy.

The clearest evidence about where this rung belongs comes from joint disease. The ACR/NPF psoriatic arthritis guideline conditionally recommends a TNF-inhibitor biologic over an oral small-molecule drug as first-line treatment for active psoriatic arthritis, and addresses tofacitinib and other orals as alternatives within that framework 4Ref 4Singh JA, Guyatt G, Ogdie A, et al. (2019).2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis.The conditional recommendation to use a TNF-inhibitor biologic over an oral small-molecule drug as first-line therapy for active psoriatic arthritis, with tofacitinib and other oral agents addressed as alternatives.. Put plainly: for skin alone an oral is often a sensible next step, but for actively inflamed joints the guideline points past it.

What this tier asks. Regular laboratory monitoring, attention to alcohol and to pregnancy planning depending on the agent, and a frank conversation about which organ each drug leans on. These are manageable, well-characterized requirements — and they are the reason this tier is supervised rather than refilled forever.

What it does not require. Failing here is not a universal prerequisite for the tier above. The AAD-NPF biologics guideline positions biologic therapy as treatment for moderate-to-severe psoriasis, not as a last resort reached only after every pill has disappointed 3Ref 3American Academy of Dermatology; National Psoriasis Foundation (2019).Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.That biologic therapy is recommended for moderate-to-severe psoriasis and is grouped by target class (TNF, IL-17, IL-23, IL-12/23), each with its own pre-treatment screening and ongoing safety monitoring..

Rung four: biologics

Biologics are injected antibodies that intercept a single inflammatory signal, and they are the most effective tier available for moderate-to-severe plaque psoriasis. The AAD-NPF guideline groups them by target — TNF, IL-17, IL-23, and the older IL-12/23 pathway — and lays out the screening required before starting and the monitoring expected during treatment for each group 3Ref 3American Academy of Dermatology; National Psoriasis Foundation (2019).Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.That biologic therapy is recommended for moderate-to-severe psoriasis and is grouped by target class (TNF, IL-17, IL-23, IL-12/23), each with its own pre-treatment screening and ongoing safety monitoring.. Which of those groups a person is offered is a substantial decision in its own right, and it is decided by more than skin.

Joints come first. Where psoriatic arthritis is active, the ACR/NPF guideline conditionally favors a TNF inhibitor as first-line therapy over an oral small molecule 4Ref 4Singh JA, Guyatt G, Ogdie A, et al. (2019).2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis.The conditional recommendation to use a TNF-inhibitor biologic over an oral small-molecule drug as first-line therapy for active psoriatic arthritis, with tofacitinib and other oral agents addressed as alternatives.. After that: existing conditions, insurance coverage, pregnancy plans, and how often a person is genuinely willing to inject.

What starting looks like. A short workup before the first dose, including tuberculosis and hepatitis screening and a look at vaccination status, then a follow-up appointment where response is assessed rather than estimated 3Ref 3American Academy of Dermatology; National Psoriasis Foundation (2019).Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.That biologic therapy is recommended for moderate-to-severe psoriasis and is grouped by target class (TNF, IL-17, IL-23, IL-12/23), each with its own pre-treatment screening and ongoing safety monitoring..

Reaching this rung is ordinary, and it is not the end of a road. For most people with extensive disease it is the tier where the daily arithmetic of managing psoriasis — the tubes, the timing, the clothing calculations — finally stops.

What runs alongside every rung

The ladder covers only the skin half of the plan. The AAD-NPF comorbidities guideline recommends that clinicians screen for and stay alert to psoriatic arthritis, cardiovascular disease, metabolic syndrome, and psychiatric comorbidity in people with psoriasis 5Ref 5American Academy of Dermatology; National Psoriasis Foundation (2019).Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities.That people with psoriasis should be screened for and monitored for psoriatic arthritis, cardiovascular disease, metabolic syndrome, and psychiatric comorbidity as part of routine psoriasis care.. Those checks belong at every level of severity, not only at the top of the ladder, and they are the part of psoriasis care most often skipped when an appointment runs short.

Joints. The most consequential thing a person can volunteer at a skin visit is a joint symptom: morning stiffness lasting beyond an hour, a finger or toe swollen along its entire length, heel pain, or back pain that eases with movement rather than rest. Joint damage does not reverse, which is why this report changes plans more often than any other 5Ref 5American Academy of Dermatology; National Psoriasis Foundation (2019).Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities.That people with psoriasis should be screened for and monitored for psoriatic arthritis, cardiovascular disease, metabolic syndrome, and psychiatric comorbidity as part of routine psoriasis care..

Metabolic and cardiovascular health. Blood pressure, lipids, glucose, and tobacco belong in the same conversation as the plaques 5Ref 5American Academy of Dermatology; National Psoriasis Foundation (2019).Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities.That people with psoriasis should be screened for and monitored for psoriatic arthritis, cardiovascular disease, metabolic syndrome, and psychiatric comorbidity as part of routine psoriasis care.. That is not a lecture about lifestyle. It is a recognition that the inflammation is not confined to what can be seen.

Mood. Visible skin disease is socially expensive, and the guideline names psychiatric comorbidity for that reason 5Ref 5American Academy of Dermatology; National Psoriasis Foundation (2019).Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities.That people with psoriasis should be screened for and monitored for psoriatic arthritis, cardiovascular disease, metabolic syndrome, and psychiatric comorbidity as part of routine psoriasis care.. Saying out loud that the disease has changed how you dress, whether you swim, or how you sleep is clinical information a dermatologist can act on.

Moving up a rung is not evidence that the earlier steps were done badly. Usually it is evidence of nothing except that the disease is more than a cream can carry.